|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 700 13th Street NW, 2nd Floor |
Address2 |
|
City | Washington |
State | DC |
Zip Code | 20005 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 313715-1003703
|
||||||||
|
6. House ID# 393840033
|
TYPE OF REPORT | 8. Year | 2022 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Allegra M. Han |
Date | 10/19/2022 8:06:30 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Update and reforms to Medicare payments for physicians and implementation of related provisions of the Medicare Access and CHIP Reauthorization Act, including: maintain patient access to In-Office Ancillary Services; implementation of Electronic Health Records meaningful use requirements; CMS implementation of misvalued codes; and Medicare sequestration.
Medicare beneficiary access to telehealth, including related provisions in H.R. 4040, the Advancing Telehealth Beyond COVID-19 Act of 2022, H.R. 1677/S. 620, the KEEP Telehealth Options Act and Discussion Draft of bipartisan Senate Finance Committee legislation, the Telemental Health Access to Care Act.
Medicare Part B reimbursement for prescription drugs and related issues to enhance patient access to covered drugs and CMMI quality initiatives, including: use of step therapy in Medicare and health insurance coverage, including related provisions in S. 464/H.R. 2163, the Safe Step Act; and H.R. 5376, Inflation Reduction Act of 2022 (Public Law No: 117-169), including provisions regarding application of Maximum Fair Prices and conforming amendments to modify Medicare Part B reimbursement for selected drugs; and physician reimbursement issues related to CMMI Most Favored Nation demonstration.
Medicare beneficiary access to drugs/advocate for relief from prior authorization requirements under Medicare Advantage and Medicare Part D plans, including related provisions in S. 3018/ H.R. 3173, and H.R. 8487, the Improving Seniors Timely Access to Care Act, and H.R. 7995, the GOLD CARD Act, to exempt qualifying physicians from prior authorization requirements under Medicare Advantage plans.
Coronavirus response and support for health care providers and patients, including related provisions in S. 3799, the PREVENT Pandemics Act, and implementation of related provisions in H.R. 1319, the American Rescue Plan Act (P.L. 117-2).
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Shannon |
Finley |
|
|
|
Denise |
Henry Morrisey |
|
|
|
Sara |
Franko |
|
|
|
Aaron K. |
Cohen |
|
|
|
Martin B. |
Gold |
|
|
|
Ann |
Jablon |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Ophthalmologists' services in Department of Veterans Affairs programs. Coronavirus response and support for health care providers and patients, including related provisions in S. 3799, the PREVENT Pandemics Act, and implementation of related provisions in H.R. 1319, the American Rescue Plan Act (P.L. 117-2). Monitor implementation of Surprise Medical Billing law. Advocacy on Risk Evaluation and Mitigation Strategy (REMS) issues, including related provisions in H.R. 6833, FY 2023 continuing appropriations, Division F, FDA User Fee Reauthorization Act [P.L. 117-180].
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Shannon |
Finley |
|
|
|
Denise |
Henry Morrisey |
|
|
|
Luke |
Hatzis |
|
|
|
Ann |
Jablon |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code VET
16. Specific lobbying issues
Legislative issues relating to vision care within the VA Health System.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Denise |
Henry Morrisey |
|
|
|
Shannon |
Finley |
|
|
|
Genny |
Beltrone |
|
Legislative Assistant, Sen. Jon Tester; Legislative Aide, Sen. Jon Tester; Legislative Correspondent, Sen. Jon Tester; Assistant to the Chief of Staff and Legislative Director, Sen. Jon Tester; Staff Assistant, Sen. Jon Tester. |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
Issues related to implementation of legislative provisions of the Indian Health Service in the Interior, Environment, and Related Agencies Appropriations bill.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Shannon |
Finley |
|
|
|
Brad |
Mollet |
|
|
|
Ann |
Jablon |
|
|
|
Joseph |
Eannello |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
Lobbyist Name | Description of Offense(s) |